Alnylam is usually developing ALN-TTR.

ALN-TTR targets a region of the gene common to wild-type and all known mutant forms of TTR, and therefore, has potential as a therapeutic for all individuals with FAC and FAP.D., Vice President, Research, Oncology and CNS at Alnylam. These data provide continued validation of our RNAi therapeutics strategy, and we are looking forward to advancing this scheduled system towards the clinic.D., Professor of Biochemistry, Molecular Neurobiology Group, Institute for Molecular and Cellular Biology in Portugal. ALN-TTR has been advanced using stable nucleic acid-lipid contaminants delivery technology in collaboration with Tekmira Pharmaceuticals Corporation.. Alnylam Pharmaceuticals presents new data from its transthyretin-mediated amyloidosis program Alnylam Pharmaceuticals, Inc.

, for the development of a highly accurate imaging diagnostic for Alzheimer’s Disease. Abiant, a privately held company, is dedicated to the application of neuroimaging to improve the procedure and medical diagnosis of neurologic and neuropsychiatric disorders. Abiant’s diagnostic strategy combines key developments in the analysis of Positron Emission Tomography pictures of the mind. The first of these originated by Lisa Mosconi, PhD, Henry Rusinek, PhD, and Wai Tsui, PhD at the NYU College of Medicine’s Center for Brain Wellness, directed by Mony de Leon, PhD. This progress allows the precise, automated measurement of glucose metabolism in the hippocampus, a mind structure that is critical to new memory formation and which can be affected very early in Alzheimer’s disease., for the development of a highly accurate imaging diagnostic for Alzheimer’s Disease. Abiant, a privately held company, is dedicated to the application of neuroimaging to improve the procedure and medical diagnosis of neurologic and neuropsychiatric disorders. Abiant’s diagnostic strategy combines key developments in the analysis of Positron Emission Tomography pictures of the mind. The first of these originated by Lisa Mosconi, PhD, Henry Rusinek, PhD, and Wai Tsui, PhD at the NYU College of Medicine’s Center for Brain Wellness, directed by Mony de Leon, PhD. This progress allows the precise, automated measurement of glucose metabolism in the hippocampus, a mind structure that is critical to new memory formation and which can be affected very early in Alzheimer’s disease.